STENOCARE shares traded on the Börse Berlin

Report this content



STENOCARE A/S (“STENOCARE”) today announces that the company’s shares have been included on the BSRM segment of the Börse Berlin under the Code number A2N6HF. STENOCARE has no relation to the broker firm which applied to Börse Berlin for the shares to be added. While STENOCARE makes no projection as to the potential impact of this development, the company’s management is positive about the possibility to increase the reach to investors in the German market. The trading on the Berlin Open Market will complement STENOCARE’s listing on Nasdaq First North Growth Market Denmark.

Germany legalized medical cannabis in 2017 and is currently one of Europe’s largest medical cannabis markets. STENOCARE’s management is therefore positive about the company’s shares being included at the Börse Berlin, which will provide the company with increased access to German investors. As has previously been announced, STENOCARE has considered alternatives for co-trading in other international markets, as a way of responding to requests from international investors. The trading at the Börse Berlin’s BSRM (Berlin Second Regulated Market), albeit not on STENOCARE’s own initiative, is therefore in line with the company’s plans and could contribute to a broader interest in STENOCARE.

Thomas Skovlund Schnegelsberg, CEO of STENOCARE, comments:

“It is certainly a good sign that we have now been informed about STENOCARE’s share being added to the Börse Berlin, which will provide us with increased visibility and access to German investors. We continue to prepare and roll-out our strategy for wider European market leadership and look forward to welcoming new shareholders from Germany and other European countries”.

For additional information regarding STENOCARE, please contact:

Thomas Skovlund Schnegelsberg, CEO
Phone: +45 31770060


STENOCARE’s Certified Adviser is Keswick Global AG, Phone: +43 1 740 408045, E-mail:

STENOCARE A/S was founded in 2017 with the purpose of supplying medical cannabis to patients in Denmark and internationally. The company was first to receive the Danish Medicines Agency's permission to import, distribute as well as cultivate and produce medical cannabis. STENOCARE is building a state-of-the-art production facility for the cultivation and production of medical cannabis at the company’s premises in Jutland, Denmark


Documents & Links